Every 424B that Profusa, Inc. (PFSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PFSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFSA filings page.
Profusa, Inc. amends its prospectus to register for resale up to 4,784 shares of common stock by Ascent Partners Fund LLC, comprised of up to 4,304 Purchase Shares and 480 Commitment Warrant Shares. The company states it will not receive proceeds from resale by the Selling Stockholder, though it may receive proceeds if it elects to sell Purchase Shares to Ascent under the Purchase Agreement, up to $100,000,000 in aggregate gross proceeds. The supplement attaches a Form 8-K disclosing a 1-for-25 reverse stock split effective July 7, 2026, which reduced outstanding shares from approximately 13.2 million to approximately 530 thousand. Exercise price for the Commitment Warrants is $0.0025, subject to adjustment and possible cashless exercise if no effective registration statement exists at exercise.
Profusa, Inc. filed a prospectus supplement registering the offer and resale of up to 23,194 shares of Common Stock by the selling stockholders. The registered shares include 13,333 Purchase Shares potentially sellable to Ascent Partners under an ELOC Purchase Agreement and various shares issuable on private placement warrants, founder, inducement and business combination-related issuances. The company will not receive proceeds from sales by the selling stockholders, though it may receive up to $100,000,000 in aggregate gross proceeds if it elects to sell Purchase Shares to Ascent. The supplement updates the prospectus to reflect a 1-for-25 Reverse Stock Split effective July 7, 2026, which reduced outstanding shares from approximately 13.2 million to approximately 530 thousand and left authorized shares at 601 million. All share and exercise amounts in the supplement are adjusted to give effect to the Reverse Stock Split.
Profusa, Inc. amended its prospectus supplement to register up to 7,170,891 shares of common stock for resale by selling stockholders, reflecting a mix of resale and issuance sources. The registered shares include 6,022,753 Purchase Shares, 801,114 Ascent Conversion Shares, 133,333 Ascent Inducement Warrant Shares, and 213,690 Sponsor Conversion Shares. The company will not receive proceeds from sales by the selling stockholders, but may receive up to $100,000,000 if it elects to sell Purchase Shares to Ascent under the ELOC Purchase Agreement and could receive up to $1,666,666.50 if all Ascent Inducement Warrants are exercised for cash. The supplement attaches a Form 8-K disclosing that Profusa effected a one-for-twenty-five (1:25) reverse stock split, reducing outstanding shares from approximately 13.2 million to approximately 530 thousand and adjusting option, warrant and plan share counts proportionately. The common stock continues to trade under the ticker PFSA.
Profusa, Inc. filed a prospectus supplement registering 22,716 shares of Common Stock for resale by selling stockholders, comprising up to 22,512 Purchase Shares and 204 transaction-cost shares. The supplement reflects a 1‑for‑25 reverse stock split effective July 7, 2026, which reduced outstanding common shares from approximately 13.2 million to approximately 530 thousand. The company states it will not receive proceeds from sales by the selling stockholders, although it may receive aggregate gross proceeds of up to $100,000,000 if it elects to sell Purchase Shares to the selling stockholder pursuant to the purchase agreement.
Profusa, Inc. filed a prospectus supplement updating its Form S-1 to register for resale up to 118,518 shares of Common Stock issuable upon conversion of convertible promissory notes held by Ascent Partners Fund LLC, representing an aggregate principal value of $22,222,222. The resale is by the selling stockholder; the company will not receive proceeds. The supplement incorporates a Form 8-K disclosing a one-for-twenty-five (1:25) reverse stock split effective July 7, 2026, which adjusted share counts and exercise/conversion terms. The reverse split reduced outstanding shares from approximately 13.2 million to approximately 530 thousand. The Ascent conversion is subject to a Beneficial Ownership Limitation (initially 4.99%, increased to 9.99% by waiver).
Profusa, Inc. registers 179,272,293 shares of Common Stock for resale by the identified selling stockholders.
The registered shares include up to 150,568,827 shares held by Ascent Partners Fund LLC under the ELOC Purchase Agreement; up to 20,027,859 shares issuable upon conversion of convertible notes (aggregate principal ~$7.0 million); up to 3,333,333 shares issuable upon exercise of an inducement warrant; and up to 5,342,274 shares issuable upon conversion of Sponsor notes (aggregate principal ~$1.9 million).
The company states it will not receive proceeds from resales by the selling stockholders, although it may receive up to $100,000,000 in aggregate gross proceeds from sales of Purchase Shares to Ascent under the ELOC Purchase Agreement. The prospectus supplement discloses a Nasdaq last sale price of $0.26 per share as of June 5, 2026.
Profusa, Inc. filed a prospectus supplement updating a resale registration that covers 179,272,293 shares of Common Stock for resale by identified selling stockholders. The resale pool includes up to 150,568,827 shares from Ascent under an equity line purchase agreement and additional shares issuable on conversion or exercise from Ascent and the Sponsor. The company will not receive proceeds from resale transactions by the selling stockholders; separately, the company may elect to sell Purchase Shares to Ascent under the ELOC Purchase Agreement for up to $100,000,000 in aggregate gross proceeds. The supplement incorporates three recent Form 8-Ks that describe Nasdaq correspondence granting an exception to continue listing subject to interim milestones, the company’s transfer to The Nasdaq Capital Market effective May 15, 2026, and an Advance Notice requesting Ascent purchase mechanics under the equity line, including a 97% VWAP funding mechanism and a True-Up Mechanism.
Profusa, Inc. files a prospectus registering up to 179,272,293 shares of Common Stock for resale by selling stockholders. This includes up to 150,568,827 Purchase Shares that the company may elect to sell to Ascent under an equity facility (ELOC) that could generate up to $100,000,000 in aggregate gross proceeds if fully used. The prospectus also registers up to 20,027,859 Ascent Conversion Shares issuable upon conversion of Ascent notes, 3,333,333 Ascent Inducement Warrant Shares, and 5,342,274 Sponsor Conversion Shares. Shares outstanding were 4,410,268 as of April 29, 2026. The Selling Stockholders may resell shares from time to time in public or private transactions; the Company will not receive proceeds from those resales but may receive proceeds from any Purchase Shares it elects to sell to Ascent and from any cash exercises of the inducement warrant.